Vectura has an innovative and broad clinical pipeline that combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors.
The respiratory pipeline comprises inhaled formulations of both branded and generic/branded generic products for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Vectura also has programmes for other diseases such as Parkinson’s disease and cystic fibrosis (CF) and is in licensing discussions for these products.
View the Product profiles